Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

Joshua O. Atiba, Stephanie J. Green, Harry E. Hynes, C. Kent Osborne, Thomas P Miller, Mark Davidner

Research output: Contribution to journalArticle

5 Scopus citations


The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalInvestigational New Drugs
Issue number2
Publication statusPublished - Jun 1994



  • breast cancer
  • cis-platinum
  • mitoxantrone
  • phase I-II trial

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this